0000899243-20-030728.txt : 20201110 0000899243-20-030728.hdr.sgml : 20201110 20201110160504 ACCESSION NUMBER: 0000899243-20-030728 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201109 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Valle Franco CENTRAL INDEX KEY: 0001699848 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 201301086 MAIL ADDRESS: STREET 1: 999 SKYWAY ROAD, SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-09 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001699848 Valle Franco C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 Senior Vice President, Finance Common Stock 2020-11-09 4 M 0 1623 7.24 A 1623 D Common Stock 2020-11-09 4 S 0 1623 74.9287 D 0 D Stock Option (Right to Buy) 7.24 2020-11-09 4 M 0 1623 0.00 D 2028-05-06 Common Stock 1623 27597 D Represents the weighted average sale price of the shares sold from $74.82 to $75.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. /s/ Franco Valle 2020-11-10